Angiogenesis as a therapeutic target in urothelial carcinoma

Anti-Cancer Drugs

Volumn 21, Issue 10, 2010, Pages 890-896

  Pinto, Álvaro ^a   Redondo, Andrés ^a   Zamora, Pilar ^a   Castelo, Beatriz ^a   Espinosa, Enrique ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Angiogenesis; Bevacizumab; Bladder cancer; Sorafenib; Sunitinib; Urothelial carcinoma

Indexed keywords

AFLIBERCEPT; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; GEFITINIB; GEMCITABINE; HYPERICIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ADJUVANT THERAPY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; HYPOXIA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY TRACT CANCER; URINARY TRACT CARCINOMA; UROTHELIAL CARCINOMA; UROTHELIUM CARCINOMA; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BENZENESULFONATES; HUMANS; INDOLES; MATRIX METALLOPROTEINASES; NEOADJUVANT THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; PYRROLES; RATS; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650046514     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833e83b2     Document Type: Review

References (71)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Charlesworth PJS, Harris AL. Mechanisms of disease: angiogenesis in urologic malignancies. Nat Clin Pract Urol 2006; 3:157-169.
3. Fox SB, Harris AL. Histological quantitation of tumor angiogenesis. APMIS 2004; 112:413-430.
4. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94:883-893.
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-257.
6. Sakamoto S, Ryan AJ, Kyprianou N. Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem 2008; 103:691-708.
7. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333:1757-1763.
8. Harris AL. Hypoxia - a key regulator factor in tumor growth. Nat Rev Cancer 2002; 2:38-47.
9. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity to hypoxia. J Biol Chem 1993; 268:21513-21518.
10. Ferrara N. VEGFR and the quest for tumor angiogenesis factors. Nat Rev Cancer 2002; 2:795-803.
11. Aragon-Ching JB, Dahut WL. Anti-angiogenesis approach to genitourinary cancer treatment. Update Cancer Ther 2009; 3:182-188.
12. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 576:66-70.
13. Jiang Y, Muschel R. Regulation of matrix metalloproteinase-9 by translational efficiency in murine prostate cancer cells. Cancer Res 2002; 62:1910-1914.
14. Kleiner D, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43:S42-S51.
15. Matrisian LM, Glaichenhaus N, Gesnel NC, Breathnach R. Epidermal growth factors and oncogenes induce transcription of the same cellular mRNA in rat fibroblasts. EMBO J 1985; 4:1435-1440.
16. Goldberg GI, Wilhelm SM, Kronberger A, Bauer EA, Grant GA, Eisen AZ. Human fibroblast collagenase. Complete primary structure and homology to an oncogene transformation-induced rat protein. J Biol Chem 1986; 261:6600-6605.
17. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996; 56:1654-1659.
18. Nemeth JA, Rafe A, Steiner M, Goolsby CL. TIMP-2 growth stimulatory activity: a concentration- and cell-type specific response in the presence of insulin. Exp Cell Res 1996; 224:110-115.
19. Bernhard EJ, Gruber SB, Muschel RJ. Direct evidence linking expression of matrix metalloproteinase 9 to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci U S A 1994; 91:4293-4297.
20. Hua J, Muschel RJ. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 1996; 56:5279-5284.
21. Kawamata H, Kameyama S, Kawai K, Tanaka Y, Nan L, Barch DH, et al. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. Int J Cancer 1995; 63:568-575.
22. Wykoff CC, Beasley NJ,Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60:7075-7083.
23. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsbrun M. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 1984; 223:1296-1299. (Pubitemid 14163183)
24. Presta M, Dell'Era P, Mitola S, Moroni E, Runca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16:159-178.
25. Cross MJ, Claesson-Welsh L. VEGF and FGF function in angiogenesis: signaling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001; 22:201-207.
26. Brown NS, Streeter EH, Jones A, Harris AL, Bicknell R. Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an ortothopic xenograft model of bladder carcinoma. Br J Cancer 2005; 92:1696-1701.
27. Pruthi RS, Derksen E, Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 2003; 169:2352-2359.
28. Goel HL, Languino LR. Integrin signaling in cancer. Cancer Treat Res 2004; 119:15-31.
29. Enenstein J, Waleh NK, Kramer RH. Basic FGF and TGF-beta differentially modulate integrin expression of human microvascular endothelial cells. Exp Cell Res 1992; 203:499-503.
30. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87:1161-1169.
31. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258:1798-1801.
32. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells upregulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997; 151:1105-1113. (Pubitemid 27424320)
33. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, et al. Involvement of interleukin-8, vascular endothelial growth factor and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997; 17:4015-4023.
34. Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth and metastasis of human melanoma. Am J Pathol 2002; 161:125-134.
35. Mian B, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappa B. Clin Cancer Res 2003; 9:3167-3175.
36. Pignot G, Bieche I, Vacher S, Güet C, Vieillefond A, Debre B, et al. Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. Eur Urol 2009; 56:678-688.
37. Wallerand H, Reiter RR, Ravaud A. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signaling pathways. Curr Opin Urol 2008; 18:524-532.
38. Neal DE, Sharples L, Smith K, Fenelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990; 65:1619-1625.
39. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20 (18 Suppl):1S-13S.
40. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5:257-265.
41. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265:1582-1584.
42. Veitonmaki N, Cao R, Wu LH, Moser TL, Li B, Pizzo SV, et al. Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for kl-5-induced antiangiogenesis. Cancer Res 2004; 64:3679-3686.
43. Tabruyn SP, Griffioen AW. Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun 2007; 355:1-5.
44. Kim YM, Hwang S, Pyun BJ, Kim TY, Lee ST, Gho YS, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002; 277:27872-27879.
45. Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. Semin Thromb Hemost 2004; 30:379-385.
46. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994; 74:762-766.
47. Chaudhary R, Bromley M, Clarke NW, Betts CD, Barnard RJ, Ryder WD, et al. Prognostic relevance of micro-vessel density in cancer of the urinary bladder. Anticancer Res 1999; 19:3479-3484.
48. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995; 87:1603-1612.
49. Bernardini S, Fauconnet S, Chabannes E, Henry PC, Adessi G, Bittard H. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001; 166:1275-1279.
50. Crew JP, O'Brien T, Bicknell R, Fuggle S, Cranston D, Harris AL. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 1999; 161:799-804.
51. Chikazawa M, Inoue K, Fukata S, Karashima T, Shuin T. Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder. Pathobiol 2008; 75:335-345.
52. Guan KP, Ye HY, Yan Z, Wang Y, Hou SK. Serum levels of endostatin and matrix metalloproteinase-9 associated with high and grade primary transitional cell carcinoma of the bladder. Urology 2003; 61:719-723.
53. Durkan GC, Nutt JE, Rajjayabun JH, Neal DE, Lunec J, Mellon JK. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Clin Cancer Res 2001; 7:3450-3456.
54. Yamanaka M, Kanda K, Li NC, Fukumori T, Oka N, Kanayama HO, et al. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 2001; 166:2495-2499.
55. Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997; 89:219-227.
56. Hahn NM, Stadler WM, Zon RT,Waterhouse DM, Picus J, Nattam SR, et al. A multicenter phase II study of cisplatin, gemcitabine and bevacizumab as first-line chemotherapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU-0475. J Clin Oncol 2009; 27:15s.
57. Hahn NM, Stadler WM, Zon RT,Waterhouse DM, Picus J, Nattam SR, et al. Mature results from Hoosier Oncology Group GU04-75 trial of cisplatine, gemcitabine and bevacizumab as first-line chemotherapy for metastatic urothelial carcinoma. J Clin Oncol 2010; 28:15s.
58. Bhuvaneswari R, Thong PS, Gan YY, Soo KC, Olivo M. Evaluation of hypericin-mediated photodynamic therapy in combination with angiogenesis inhibitor bevacizumab using in vivo fluorescence confocal microscopy. J Biomed Opt 2010; 15:011114.
59. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, et al. Phase II trial of aflibercept (VEGF-trap) in patients with recurrent or metastatic transitional cell carcinoma of the urothelium: a California Cancer Consortium trial [abstract]. J Clin Oncol 2009; 27:e16030.
60. Bellmunt J, Gonzalez-Larriba JL, Maroto JP, Carles J, Castellano DE, Mellado B, et al. First-line treatment with sunitinib monotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit. J Clin Oncol 2010; 28:15s.
61. Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010; 28:1373-1379.
62. Galsky MD, Sonpavde G, Hellerstedt BA, McKinney SA, Hutson TE, Rauch MA, et al. Phase II study of gemcitabine, cisplatin and sunitinib in advanced urothelial carcinoma. J Clin Oncol 2010; 28:15s.
63. Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth RJ, et al. Phase II trial of sorafenib in patients with advanced urothelial cancer. Cancer 2009; 115:4090-4095.
64. Krege S, Rexer H, vom Dorp F, Albers P, de Geeter P, Klotz T. Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05). J Clin Oncol 2010; 28:15s.
65. Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, et al. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int 2009; 103:1729-1737.
66. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6:4874-4884. (Pubitemid 32110432)
67. Alva AS, Agarwal N, Siefker-Radtke AO, Roth BJ, Smith DC, Daignault S, et al. Targeting epidermal growth factor receptor in urothelial cancer: a phase II randomized trial of cisplatin with gemcitabine with or without cetuximab. J Clin Oncol 2010; 28:15s.
68. Bhuvaneswari R, Gan YY, Soo KC, Olivo M. Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer 2009; 8:94.
69. Nicolle G, Daher A, Maille P, Vermey M, Loric S, Bakkar A, et al. Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation. Clin Cancer Res 2006; 12:2937-2943.
70. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ. A phase II trial of cisplatin, gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 2009; 20:1074-1079.
71. Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, Goodwin JW, Twardowski PW, Atkins JN, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 2010; 105:317-321.